Display Settings:

Format

Send to:

Choose Destination
    Int J Rheumatol. 2011;2011:804296. Epub 2011 Sep 12.

    Low-dose naltrexone for pruritus in systemic sclerosis.

    Source

    Division of Rheumatology, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA.

    Abstract

    Pruritus is a common symptom in systemic sclerosis (SSc), an autoimmune disease which causes fibrosis and vasculopathy in skin, lung, and gastrointestinal tract (GIT). Unfortunately, pruritus has limited treatment options in this disease. Pilot trials of low-dose naltrexone hydrochloride (LDN) for pruritus, pain, and quality of life (QOL) in other GIT diseases have been successful. In this case series we report three patients that had significant improvement in pruritus and total GIT symptoms as measured by the 10-point faces scale and the University of California Los Angeles Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0) questionnaire. This small case series suggests LDN may be an effective, highly tolerable, and inexpensive treatment for pruritus and GIT symptoms in SSc.

    PMID:
    21918649
    [PubMed]
    PMCID:
    PMC3171757
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Figure 1
    Figure 2

      Supplemental Content

      Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk